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Abstract
This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, 
which was held on 15th–17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual’s 
immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced 
cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and 
immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies 
include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update 
on where we are at present.
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Session 1: The laboratory background and current developments
Sandrine Aspeslagh from Gustave Roussy gave a presentation entitled ‘The experimental evidence for immune-mediated cell death 
during chemotherapy and radiotherapy’. She discussed the mechanisms and key importance of immunogenic cell death (ICD). She also 
discussed the mechanism of activation of the immune system which is triggered by the cellular stress generated by chemotherapy, and 
how it is thought to be essential for treatment response and induction of a durable post-chemotherapy immunity. Tumours which lack this 
mechanism respond less well to treatment and have a worse prognosis. Several types of conventional anti-cancer treatments such as 
chemotherapy and radiotherapy do elicit ICD and will lead to therapeutic success in immunocompetent but not immunodeficient hosts. 
This type of cell death will activate immune pathways involving calreticulin, ATP, and HMGB1 leading to a more adequate immune reaction 
towards the cancer cells and as such enhance the anti-tumour potential. In the era of immune checkpoint blockade it is of the utmost impor-
tance to understand these mechanisms in order to propose better rational combinatorial regimens for immune checkpoint resistant patients.
Andrea Anichini from the National Tumour Institute in Milan discussed ‘Technologies and current translational approaches in immuno-
therapy’. Over the past six years, results of several Phase I to III clinical trials of cancer immunotherapy targeting immune checkpoints 
(initially CTLA-4 and subsequently the PD-1/PD-L1 axis) have fostered the dawn of a new era in the treatment of several advanced cancers 
including melanoma, non-small cell lung cancer (NSCLC), urothelial cancer, renal cancer, head and neck squamous cell carcinoma, triple- 
negative breast cancer, gastric cancer, colorectal cancer, Merkel cell carcinomas, and Hodgkin’s lymphomas. In spite of these remarkable 
improvements in treatment of several advanced cancers, only a fraction of patients achieve clinical benefit from immunotherapy. The recent 
technological developments in the fields of pathology and immunopathology and of genomic and immunological analysis of neoplastic 
lesions have fostered the development of effective translational approaches that allow to understand the mechanisms of response and 
resistance to immunotherapy. It helps define which tumour subsets have a molecular and immunological profile that favours response to 
immunotherapy and also to identify predictive markers of response and resistance.
The first relevant development has been the introduction of the genomic analysis techniques that allows the profiling of all non-synonymous 
mutations existing in a tumour sample and to then infer the overall mutational burden and the neo-antigen load of each lesion. The rel-
evance of the neo-antigen load in different solid tumours is a main predictive factor of response to immunotherapy.
A further remarkable technological improvement has been the introduction of fluorescence-based microscopy platforms that allow the 
development of quantitative and multi-parametric pathological analysis of tissues. These tools enable pathologists and immunologists 
to count single immune or stromal or neoplastic cells in the lesions and to understand the relative topological relationships in the light of 
the specific phenotypic and functional properties of each subset. The latter development is providing a quantitative means to assess key 
predictive parameters of response to immunotherapy as well as the immunoscore and the overall immune contexture for the pre- and post-
therapy lesions.
Further translational approaches that are proving to be key tools of immunological investigation in the context of immunotherapy include 
techniques that allow the gene expression profiles to be measured in formalin-fixed, paraffin-embedded (FFPE)tissue. This enables one to 
understand whether a specific lesion has an active immune-related gene programme.
Finally, all existing experimental approaches, such as multiparametric flow cytometry and mass cytometry, that allow the ex-vivo analysis 
of function and antigen-specificity of T cells isolated from surgical samples help contribute to validate the potentially relevant neo-antigens 
that in each specific lesion are targeted by the immune system.
Jon Amund Kyte from Oslo University Hospital, Norway discussed ‘Adoptive cellular therapy approaches and early clinical studies’.
Adoptive cell therapy (ACT) with tumour-infiltrating lymphocytes in cancer therapy is already in use for the treatment of metastatic mela-
noma. More recently, modern gene engineering technology has opened for reprogramming the patient’s own T cells with tumour-targeting 
T cell receptors (TCRs) or chimeric antigen receptors (CARs). These T cells are then expanded to millions of tumour-specific ‘missiles’ and 
given back to the patient. A number of CAR T cell studies have shown remarkable clinical responses in heavily pre-treated patients with 
acute lymphoblastic leukaemia (80–90% complete responses), chronic lymphocytic leukaemia or B-cell lymphomas. The CARs represent 
optimised TCRs, comprising of an extracellular antigen binding single chain fragment variable (scFv) from a monoclonal antibody (mAb) 
and signalling domains from the TCR complex. Contrary to TCRs, the CAR binds in an HLA-independent manner and may be used across 
the entire patient population. While CARs can only target surface antigens, TCRs also recognise intracellular antigens which greatly broad-
ens the spectrum available targets. ACT with redirected T cells has not yet shown efficacy against solid cancers. A number of approaches 
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are currently investigated to address this limitation. Key areas of research include attempts to identify better target antigens, strategies to 
overcome established tolerance in solid tumours, and approaches for personalising the therapy by targeting patient-specific neo-antigens.
Christian Blank from the Netherlands Cancer Institute discussed the impact of cancer immunotherapy on clinical cancer care. Inhibitors of 
T cell checkpoints, such as PD-1 and CTLA-4, are showing clinical activity in a variety of human malignancies. The infusion of autologous 
tumour-infiltrating T cells has shown activity in melanoma and may also be of value in HPV positive cancers. Also the infusion of gene-
modified T cells is showing clinical activity in particular for B cell malignancies. It is important to realise that these different immunotherapies 
remedy distinct ‘problems’ in tumour–immune interactions. For instance, PD-1 blockade is considered to primarily unleash the activity of an 
already tumour-resident T cell pool. In contrast, in addition to a possible effect at the tumour site, CTLA-4 blockade is thought to enhance 
tumour-specific T cell responses. Finally, gene-modified T cell therapies assume that the endogenous T cell compartment is insufficient, 
and a creation of a novel T cell compartment is the hurdle that needs to be taken to achieve tumour regression. There is also a question of 
what would be the most effective therapy for an individual patient?
Dr Blank outlined a framework to describe the interaction between cancer and immune system in individual cases, and that—on the basis 
of biomarker assays—may help predict which specific aspect of cancer–immune interaction should be the target for therapy. This Cancer 
Immunogram builds on two key observations. First, the outcome of cancer–immune interactions is based on a number of largely unre-
lated parameters, including aspects such as tumour foreignness and a series of T cell inhibitory mechanisms. Second, the ‘value’ of these 
parameters differs greatly between individual patients. As an example, while in some patients intratumoural inhibition of tumour-specific 
T cells will be the sole defect that needs to be addressed, in other patients the tumour may simply be insufficiently foreign to mount a clini-
cally relevant T cell response in the first place. Because of this multifactorial nature of cancer–immune interactions, only combinations of 
biomarker assays can be expected to best reveal which aspect of cancer–immune interaction should be the focus in individual cases. In 
addition to describing which defects in cancer–immune interaction need to be remedied, the Cancer Immunogram should also be useful to 
discuss in which cases a given treatment option may not be needed. As a clinically relevant example, it is unclear whether in patients with 
an existing tumour-specific T cell response combined blockade of PD-1 and CTLA-4 will be preferable over single agent PD-1 blockade, 
both because of the toxicity associated with (combination) treatment and the very significant treatment costs of cancer immunotherapies.
Session 2: Clinical immunotherapy and combinations
The first presentationof the afternoon ‘Immune checkpoint inhibitors and combination approaches: current status and future perspectives’ 
was by Paolo Ascierto from the National Tumour Institute in Naples, Italy. Until recently, most immunotherapeutic approaches used to 
combat cancer were ineffective, counteracted by the tumour’s ability to evade immune attack. However, extensive research has improved 
our understanding of tumour immunology and enabled the development of novel treatments that can harness the patient’s immune system 
and prevent immune escape. Over the last few years, through numerous clinical trials and real-world experience, we have accumulated 
a large amount of evidence regarding the potential for long-term survival with immunotherapy agents in various types of malignancy [1].
In 2011, the approval of ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 monoclonal antibody, for the treatment 
of metastatic melanoma represented the first step in a new era for immunotherapy. Subsequently, promising survival results have been 
achieved with the anti- programmed death (PD)-1 antibodies nivolumab and pembrolizumab in patients with various cancers that as well 
as advanced melanoma include non-small-cell lung cancer and renal cell cancer. These and other immunotherapy agents in development 
have been heralded as potential turning point in the treatment of cancer.
Given the numerous immune checkpoints that exist and the multiple mechanisms used by tumours to escape the immune system, 
targeting distinct checkpoint pathways using various combination approaches is an attractive therapeutic strategy with the potential to 
further enhance the antitumour immune response. Several clinical studies have shown that combining different immunotherapies can 
improve outcomes and more likely to offer additional clinical benefit compared with single-agent therapies. Immunotherapies are also 
being assessed in combination with other treatment modalities including chemotherapy, targeted agents, and radiation.
Although the research focus and main advances have to date been largely on melanoma, immunotherapies are being actively investigated 
in many other cancer types including those where treatment options for patients are limited. Currently ongoing and planned studies should 
help bring the benefits of these novel immunotherapies within the reach of patients with a wide range of cancers.
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Nicolle Rekers from the Maastricht University Medical Centre–The Netherlands gave a presentation on ‘Combining radiotherapy and 
cancer immunotherapy: a paradigm shift?’
There is conclusive evidence that apart from its direct effects, radiotherapy (RT) can initiate an immune response. Previously, we have 
shown that the addition of L19-IL2 to RT was able to drastically increase the immune response, and that this combination therapy resulted 
in a long-lasting synergistic anti-tumour effect. Rekers hypothesised that tumour cells outside the radiation field would also be eliminated 
by this combination treatment (abscopal effect) and that tumours cannot be formed again after re-challenging cured animals (memory 
effect). In fact RT+L19-IL2 was able to cure 100% of primary tumours and was associated with an increased percentage of CD8+ T cells 
inside these irradiated tumours. When a single RT dose of 15 Gy was combined with L19-IL2, 20% of the non-irradiated secondary tumours 
were cured. Interestingly, the non-irradiated tumours of mice treated with 15 Gy+L19-IL2 showed a significant (p < 0.01) increased per-
centage of CD4+ T cells compared to irradiated tumours. Fractionated radiotherapy combined with L19-IL2 caused a significant (p < 0.01) 
growth delay in the non-irradiated tumours, however, no secondary tumours were cured. Immunological analysis revealed an increase in 
PD-1 expression on T cells infiltrating these tumours, suggesting a more regulatory phenotype after fractionated radiotherapy compared 
with one single RT dose. Moreover, it is observed that new C51 tumours were not able to form in cured mice whereas 100% of the age-
matched control mice formed tumours that reached established end-points within 17 days. Splenic T cells of these cured mice were associ-
ated with a high expression of CD127, a receptor associated with memory potential.
In conclusion the data show that RT+L19-IL2 causes anti-tumour immune effects also outside the radiation field, and that this effect is 
associated with an increase of CD4+ T cells. Cured mice were not able to form new tumours and have a high expression of CD127 on their 
T cells suggesting these cells have an immunological memory. This new treatment will be further investigated in a Phase I study for patients 
with an oligometastatic solid tumour (NCT02086721).
‘Cancer vaccines: still a viable approach?’ was the title of Per Thor Straten’s (University of Copenhagen) talk. He discussed the require-
ments for construction of this vaccine, the differences in preventive and therapeutic vaccinations and the associated immune responses, 
how and why cancer cells are targeted and the antigens recognised. A couple of examples of vaccine trials including a short sum-up of the 
FDA/EMA approved Sipuleu cell T were discussed along with the nature of clinical responses upon vaccination–and based on that–some 
discussion slides on whether therapeutic vaccination against cancer is still (if it ever was...) a viable approach....
Finally, the ‘Implications of modern immunotherapy on the organisation of healthcare in cancer centres’ was presented by Ahmad Awada 
(Institut Jules Bordet, Belgium).
This important therapeutic development of modern immunotherapy will surely have implications on the organisation of healthcare in cancer 
centres. Dr Awada discussed the reasons for this and these are summed up below:
•	 Potentially	more	patients	will	survive	cancers.	Medical	problems	of	survivors	should	be	managed	optimally	by	cancer	centres.	
•	 There	will	be	an	increase	in	the	number	of	patients	treated,	for	long	periods	of	time,	at	outpatient	clinics.	
•	 Predictive	markers	 of	 sensitivity/resistance	 will	 be	 developed.	 Pathology	 and	molecular	 biology	 departments	 should	 follow	 and	
implement these advances.
•	 Modern	 immunotherapy	will	have	several	organ-related	adverse	events.	An	multidisciplinary	approach	(including	oncologists	and	
internal medicine specialists) is needed to tackle these adverse events. 
•	 Adoptive	cell	 therapies	are	developing.	Only	specialised	cancer	 institutes	and	university	centres	will	be	able	 to	 implement	 these	
approaches. 
•	 Immunotherapy	is	beneficial	in	nearly	all	solid	and	some	haematological	malignancies.	A	‘transversal’	immunotherapy	unit	for	clinical	
and research aspects should be created in cancer centres. 
•	 More	 and	 more	 patients	 are	 responding	 partially	 to	 these	 therapies.	 Consolidating	 this	 benefit	 with	 local	 therapy	 (surgery,	
radiofrequency, local radiotherapy...) should be developed and organised within the treating cancer centre.
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